Resmed remains the best performer of biotech's Big Four, but some investors aren't sleeping tight after last week's $700 ...

The developer of a drug for the rare multiple system atrophy, Alterity will launch a pivotal phase III trial after a go-ahead ...

The results, including 7.3m at 11.0% lead and 89g/t silver, sit 120m from a fully permitted exploration decline.

A growing number of ASX companies are targeting brownfields opportunities in proven mining districts to fast-track their ...

Oil shock rattles the ASX; Energy stocks join the party; Genesis and Vault agree to $5.6bn gold deal; The S&P/ASX 200 was ...

The ASX was little changed after a US-imposed Strait of Hormuz toll sent crude soaring, lifting energy stocks as precious ...

The developer of cannabis-based therapies for childhood disorders, Neurotech has won valuable Investigational New Drug status ...

We are entering a new phase for global investment markets where the winners and losers will be separated by the degree to ...

Queue up the USC Trojan Marching Band and dial up Lindsay Buckingham because Tusker is the name reverberating for small cap ...

A South Korean giant’s decades-long pursuit of its own feedstocks is drawing another generation of juniors into its orbit.

A step-change upgrade to the gold inventory lifts resources and reserves as OBM builds a larger, longer-life production ...